BT-0267

BT-0267 is a novel, orally bioavailable small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), developed by Brenig Therapeutics for the treatment of Parkinson's disease. LRRK2 is a key protein implicated in the pathogenesis of Parkinson’s disease, and its inhibition represents a promising disease-modifying therapeutic strategy. Designed using advanced computer-aided drug design and artificial intelligence approaches, BT-0267 demonstrates high selectivity (1000x over other kinases and >500x over other safety panel targets) and efficient blood-brain barrier penetration with minimized peripheral exposure. Preclinical studies show an outstanding cerebrospinal fluid (CSF)/unbound plasma ratio in non-human primates, excellent pharmacokinetics, minimal or no visible lung or kidney toxicity at high doses, and robust efficacy in brain tissue. The compound is currently advancing through early clinical development as a potential best-in-class therapy for both idiopathic Parkinson’s disease and cases associated with LRRK2 mutations[1][3][4][5][6][8].

Other names

BT 267BT267BT-267